Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

被引：1

作者：

Hu, Yuxuan ^{[1
]}

Wang, Yanning ^{[2
]}

Shao, Taihang ^{[3
]}

Tang, Wenxi ^{[3
]}

Hu, Kerong ^{[4
]}

Zhou, Yujie ^{[5
]}

Miao, Liyun ^{[5
]}

Liu, Jing ^{[6
]}

Wang, Bin ^{[2
]}

Yu, Wenying ^{[1
]}

机构：

[1] China Pharmaceut Univ, Inst Pharmaceut Sci, Nanjing 211198, Peoples R China

[2] Nanjing Univ, Affiliated Drum Tower Hosp, Clin Stem Cell Ctr, Med Sch, 321 Zhongshan Rd, Nanjing 210008, Peoples R China

[3] China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Pharmacoecon, Nanjing 211198, Peoples R China

[4] Huangshi Love & Hlth Hosp, Dept Infect Dis, Huangshi 435000, Peoples R China

[5] Nanjing Drum Tower Hosp, Dept Resp & Crit Care Med, Nanjing 210008, Peoples R China

[6] Nanjing Yuhua Hosp, Nanjing Hosp 1, Yuhua Branch, Clin Lab, Nanjing 210039, Peoples R China

来源：

VACCINE | 2023年 / 41卷 / 18期

关键词：

COVID-19; SARS-CoV-2; Heterologous vaccination; Immunogenicity; Meta-analysis; NCOV-19;

D O I：

10.1016/j.vaccine.2023.03.056

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/ BNT vaccination regimens.Materials and methods: We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165.Results: Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety.Discussion: Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页码：3003 / 3010

页数：8

共 50 条

[21] Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies
Radhwi, Osman O.
Jan, Hamza
Waheeb, Abdullah
Alamri, Sawsan S.
Alahwal, Hatem M.
Denetiu, Iuliana
Almanzlawey, Ashgan
Al-Marzouki, Adel F.
Almohammadi, Abdullah T.
Bahashwan, Salem M.
Barefah, Ahmed S.
Qari, Mohamad H.
Abuzenadah, Adel M.
Hashem, Anwar M.
VACCINES, 2022, 10 (02)
[22] Differences in the immunogenicity of heterologous Ad26.COV.2/BNT162b2 vaccination compared to other heterologous and homologous COVID-19 vaccine regimens
Klemis, V.
Venhorst, A.
Halmans, L.
Schmidt, T.
Greiss, F.
Wilhelm, A.
Widera, M.
Sester, U.
Gaertner, B. C.
Meyer, T.
Sester, M.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 165 - 166
[23] Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
Hammerschmidt, Swantje I.
Bosnjak, Berislav
Bernhardt, Guenter
Friedrichsen, Michaela
Ravens, Inga
Dopfer-Jablonka, Alexandra
Hoffmann, Markus
Pohlmann, Stefan
Behrens, Georg M. N.
Foerster, Reinhold
CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (10) : 2455 - 2456
[24] Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
Swantje I. Hammerschmidt
Berislav Bosnjak
Günter Bernhardt
Michaela Friedrichsen
Inga Ravens
Alexandra Dopfer-Jablonka
Markus Hoffmann
Stefan Pöhlmann
Georg M. N. Behrens
Reinhold Förster
Cellular & Molecular Immunology, 2021, 18 : 2455 - 2456
[25] Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Barros-Martins, Joana
Hammerschmidt, Swantje, I
Cossmann, Anne
Odak, Ivan
Stankov, Metodi, V
Ramos, Gema Morillas
Dopfer-Jablonka, Alexandra
Heidemann, Annika
Ritter, Christiane
Friedrichsen, Michaela
Schultze-Florey, Christian
Ravens, Inga
Willenzon, Stefanie
Bubke, Anja
Ristenpart, Jasmin
Janssen, Anika
Ssebyatika, George
Bernhardt, Gunter
Muench, Jan
Hoffmann, Markus
Poehlmann, Stefan
Krey, Thomas
Bosnjak, Berislav
Foerster, Reinhold
Behrens, Georg M. N.
NATURE MEDICINE, 2021, 27 (09) : 1525 - +
[26] Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
Chatsiricharoenkul, Somruedee
Niyomnaitham, Suvimol
Posen, Harry Joshua
Toh, Zheng Quan
Licciardi, Paul V.
Wongprompitak, Patimaporn
Duangchinda, Thaneeya
Pakchotanon, Pattarakul
Chantima, Warangkana
Chokephaibulkit, Kulkanya
FRONTIERS IN IMMUNOLOGY, 2022, 13
[27] Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins
Swantje I. Hammerschmidt
Anne Cossmann
Ivan Odak
Metodi V. Stankov
Gema Morillas Ramos
Alexandra Dopfer-Jablonka
Annika Heidemann
Christiane Ritter
Michaela Friedrichsen
Christian Schultze-Florey
Inga Ravens
Stefanie Willenzon
Anja Bubke
Jasmin Ristenpart
Anika Janssen
George Ssebyatika
Günter Bernhardt
Jan Münch
Markus Hoffmann
Stefan Pöhlmann
Thomas Krey
Berislav Bošnjak
Reinhold Förster
Georg M. N. Behrens
Nature Medicine, 2021, 27 : 1525 - 1529
[28] Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
Hillus, David
Schwarz, Tatjana
Tober-Lau, Pinkus
Vanshylla, Kanika
Hastor, Hana
Thibeault, Charlotte
Jentzsch, Stefanie
Helbig, Elisa T.
Lippert, Lena J.
Tscheak, Patricia
Schmidt, Marie Luisa
Riege, Johanna
Solarek, Andre
von Kalle, Christof
Dang-Heine, Chantip
Gruell, Henning
Kopankiewicz, Piotr
Suttorp, Norbert
Drosten, Christian
Bias, Harald
Seybold, Joachim
Klein, Florian
Kurth, Florian
Corman, Victor Max
Sander, Leif Erik
LANCET RESPIRATORY MEDICINE, 2021, 9 (11): : 1255 - 1265
[29] Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
Vogel, Emanuel
Kocher, Katharina
Priller, Alina
Cheng, Cho-Chin
Steininger, Philipp
Liao, Bo-Hung
Korber, Nina
Willmann, Annika
Irrgang, Pascal
Held, Juergen
Moosmann, Carolin
Schmidt, Viviane
Beileke, Stephanie
Wytopil, Monika
Heringer, Sarah
Bauer, Tanja
Brockhoff, Ronja
Jeske, Samuel
Mijocevic, Hrvoje
Christa, Catharina
Salmanton-Garcia, Jon
Tinnefeld, Kathrin
Bogdan, Christian
Yazici, Sarah
Knolle, Percy
Cornely, Oliver A.
Ueberla, Klaus
Protzer, Ulrike
Schober, Kilian
Tenbusch, Matthias
EBIOMEDICINE, 2022, 85
[30] Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
Barocci, Simone
Orlandi, Chiara
Diotallevi, Aurora
Buffi, Gloria
Ceccarelli, Marcello
Vandini, Daniela
Carlotti, Eugenio
Galluzzi, Luca
Rocchi, Marco Bruno Luigi
Magnani, Mauro
Casabianca, Anna
VACCINES, 2022, 10 (04)

← 1 2 3 4 5 →